Platinum-Gold Compounds as Potential Chemo- and Targeted Agents for Ovarian Cancer
铂金化合物作为卵巢癌的潜在化疗药物和靶向药物
基本信息
- 批准号:10627602
- 负责人:
- 金额:$ 16.62万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-04 至 2027-06-30
- 项目状态:未结题
- 来源:
- 关键词:Advanced DevelopmentAffectAftercareAntibody-drug conjugatesAntineoplastic AgentsBiologicalBiological AvailabilityCancer cell lineCarboplatinCell CycleCell DeathCell LineCisplatinClinicClinicalCouplingDNADiagnosisDiseaseDose LimitingEncapsulatedEpidermal Growth Factor ReceptorEpithelial ovarian cancerEvaluationFDA approvedFormulationGeneticGeometryGlutathione S-TransferaseGoldGold CompoundsGrantHealthHumanImmunoliposomeIn VitroInvadedInvestigationKDR geneLigandsLip structureLiposomesMaintenance TherapyMalignant Female Reproductive System NeoplasmMalignant NeoplasmsMalignant neoplasm of ovaryMetalsMethodsModelingMonoclonal AntibodiesMusNewly DiagnosedOperative Surgical ProceduresOvarianPaclitaxelParentsPatientsPharmaceutical PreparationsPlatinumPoly(ADP-ribose) Polymerase InhibitorPositioning AttributePostmenopausePropertyPublic HealthRecurrenceResearchResearch TrainingResistanceSolubilityStudentsSurvival RateSystemTherapeuticTimeTrastuzumabTumor DebulkingUnited StatesWomanWorkangiogenesisanti-PD1 antibodiesanti-cancercancer cellcarboxylatecarboxylationcell growthchemotherapycytotoxiccytotoxicitydocetaxeldrug developmentexpectationimmunogenic cell deathimprovedin vivoinnovationinsightintravenous administrationmigrationmortalityneoplastic celloxaliplatinpharmacologicstandard of caretargeted agenttargeted deliverytargeted treatmentthioredoxin reductasetumorvector
项目摘要
PROJECT SUMMARY
Ovarian cancer (OC) is the fifth in cancer mortality for women, and it is the deadliest for all types
of gynecological cancers, affecting mainly postmenopausal women. In 80% of the cases the
diagnosis comes at stages III and IV with 28% survival rate. The standard of care of OC is
debulking surgery followed by platinum-based chemotherapy. FDA-approved platinum (II)
compounds (cisplatin, carboplatin and oxaliplatin) present major drawbacks for OC which are: a)
the acquired resistance of cancer cells after treatment, and b) the lack of selectivity which causes
undesired secondary effects due to dose limiting effects. For as many as 62% patients the disease
will recur after receiving chemotherapy, and maintenance therapies are required. Modified Pt(IV)
compounds hold the potential to become alternatives to Pt(II)-based drugs, especially for OC, for
which resistance to the treatment is a major problem, and for which first-line chemotherapy
treatment may still be the most affordable option for years. This proposal aims to develop Platinum
(IV)-Gold anticancer agents with potential dual- or multi-drug effects with improved
pharmacological profile with respect to FDA-approved Pt(II) compounds. Our hypothesis is that
the reduction of the heterometallic Pt(IV) compounds inside OC cells, will release not only
conventional Pt(II) anticancer agents, but also highly cytotoxic gold derivatives that will target
different biomolecules in the tumors and favor immunogenic cell death, overriding resistance. The
specific aims of this proposal are: Aim 1. Synthesis and in vitro Evaluation of New Platinum(IV)-
Gold Compounds in Ovarian Cancer Cell Lines. We will synthesize new Pt(IV)-Au(I) and Pt(IV)-
Au(III) compounds and study their stability and interactions with DNA (target for Pt(II)
compounds). We will evaluate their effects on a panel of epithelial ovarian cancer cell lines with
varying degrees of genetic complexity, as well as on non-tumorigenic cell lines. For selected
compounds, we will study their effects on other cancer hallmarks (migration, invasion and
angiogenesis), on cell death and cell cycle, and inhibition of gold compounds’ targets. Aim 2.
Optimize the Formulation and Targeting Properties of Selected Pt-Au Compounds. Preliminary in
vivo Investigation. We will encapsulate best performing Pt-Au compounds into liposomes and
immunoliposomes to further improve the safe delivery of these derivatives. In addition, we will
assess the survival of mice treated with two selected Pt-Au compound and their two formulations
(Pt-Au-Lip and Pt-Au-ImmunoLip) on a mouse metastatic orthotopic model (ovarian cell line
resistant to cisplatin, C200) and compare it to that of those treated with cisplatin and carboplatin.
项目摘要
卵巢癌(OC)是女性癌症死亡率的第五位,也是所有类型中最致命的
妇科癌症,主要影响绝经后妇女。在80%的情况下,
诊断为III期和IV期,存活率为28%。OC的护理标准是
减瘤手术后进行铂类化疗。FDA批准的铂(II)
化合物(顺铂、卡铂和奥沙利铂)对OC存在主要缺点,其为:a)
治疗后癌细胞的获得性抗性,和B)缺乏选择性,
由于剂量限制效应导致的不希望的二次效应。对于多达62%的患者,
接受化疗后会复发,需要维持治疗。改性Pt(IV)
化合物有可能成为Pt(II)基药物的替代品,特别是OC,
对治疗的耐药性是一个主要问题,而一线化疗
治疗可能仍然是多年来最负担得起的选择。该提案旨在开发铂金
(IV)-具有潜在的双重或多重药物作用的金抗癌剂,
FDA批准的Pt(II)化合物的药理学特征。我们的假设是
OC细胞内的异金属Pt(IV)化合物的还原不仅会释放出
传统的Pt(II)抗癌剂,但也有高度细胞毒性的金衍生物,
不同的生物分子在肿瘤中,并有利于免疫原性细胞死亡,压倒性的阻力。的
该提案的具体目标是:目标1。新型铂(IV)的合成及体外评价
卵巢癌细胞系中的金化合物我们将合成新的Pt(IV)-Au(I)和Pt(IV)-
Au(III)化合物,并研究它们的稳定性和与DNA的相互作用(Pt(II)的目标)
化合物)。我们将评估它们对一组上皮性卵巢癌细胞系的作用,
不同程度的遗传复杂性,以及非致瘤细胞系。为选定
化合物,我们将研究它们对其他癌症标志(迁移,侵袭和
血管生成)、对细胞死亡和细胞周期的影响,以及抑制金化合物的靶标。目标二。
优化所选Pt-Au化合物的配方和靶向特性。初步的
体内研究。我们将把性能最好的Pt-Au化合物封装到脂质体中,
免疫脂质体,以进一步改善这些衍生物的安全递送。此外,我们将
评估用两种选择的Pt-Au化合物及其两种制剂处理的小鼠的存活率
(Pt-Au-Lip和Pt-Au-ImmunoLip)对小鼠转移性原位模型(卵巢细胞系)的作用
顺铂耐药,C200),并将其与顺铂和卡铂治疗的患者进行比较。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Maria Contel其他文献
Maria Contel的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Maria Contel', 18)}}的其他基金
Biodegradable nanocarriers and antibodies as targeting delivery vehicles for cancer metallodrugs
可生物降解的纳米载体和抗体作为癌症金属药物的靶向递送载体
- 批准号:
10153816 - 财政年份:2018
- 资助金额:
$ 16.62万 - 项目类别:
Titanium-gold-based chemotherapeutics for prostate and kidney cancer
用于前列腺癌和肾癌的钛金化疗药物
- 批准号:
9089601 - 财政年份:2013
- 资助金额:
$ 16.62万 - 项目类别:
Titanium-gold-based chemotherapeutics for prostate and kidney cancer
用于前列腺癌和肾癌的钛金化疗药物
- 批准号:
8884396 - 财政年份:2013
- 资助金额:
$ 16.62万 - 项目类别:
Titanium-gold-based chemotherapeutics for prostate and kidney cancer
用于前列腺癌和肾癌的钛金化疗药物
- 批准号:
8474078 - 财政年份:2013
- 资助金额:
$ 16.62万 - 项目类别:
Titanium-gold-based chemotherapeutics for prostate and kidney cancer
用于前列腺癌和肾癌的钛金化疗药物
- 批准号:
8677829 - 财政年份:2013
- 资助金额:
$ 16.62万 - 项目类别:
Organogold phosphorus-containing compounds as antitumor agents
有机金含磷化合物作为抗肿瘤剂
- 批准号:
8215732 - 财政年份:2010
- 资助金额:
$ 16.62万 - 项目类别:
Organogold phosphorus-containing compounds as antitumor agents
有机金含磷化合物作为抗肿瘤剂
- 批准号:
8012810 - 财政年份:2010
- 资助金额:
$ 16.62万 - 项目类别:
Organogold phosphorus-containing compounds as antitumor agents
有机金含磷化合物作为抗肿瘤剂
- 批准号:
7761457 - 财政年份:2010
- 资助金额:
$ 16.62万 - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
$ 16.62万 - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
$ 16.62万 - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
$ 16.62万 - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
$ 16.62万 - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
$ 16.62万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
$ 16.62万 - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
$ 16.62万 - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
$ 16.62万 - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
$ 16.62万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
$ 16.62万 - 项目类别:
Studentship